ArticleEuropean urology open science2025
Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Agreement of axial T2-MRI versus Contrast-Enhanced CT for solid renal mass active surveillance.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates of <10-20%. Questions remain regarding the durability of AS when applied so broadly. We evaluated the oncologic outcomes of patients at 1, 2, and 3 yr after the initiation of AS, including survival and delayed intervention rates, hypothesizing that these will be comparable to prior reports. Methods: Between May 2017 and September 2023, data regarding 2161 (52% of 4178) patients with cT1RMs who initiated AS at Michigan Urological Surgery Improvement Collaborative (MUSIC) practices were reviewed. Factors associated with staying on AS were analyzed. Overall survival and the cumulative incidence of treatment were assessed using the Kaplan-Meier method. Key findings and limitations: In total, 2161 patients from 21 practices initiated AS, including 51% with tumors of ≤2 cm, 26% with tumors of 2.1-3.0 cm, and 24% with tumors of 3.1-7.0 cm. At 36 mo, overall survival was 90%, with metastasis and death from kidney cancer in only one patient who refused intervention. The cumulative incidence rates of treatment were 6%, 11%, and 13% at 1, 2, and 3 yr, respectively, with 9.6% for ≤2 cm, 16% for 2.1-3.0 cm, and 18% for >3 cm tumors at 3 yr. Limitations include the study's retrospective review of prospectively enrolled data limiting conclusions beyond 3 yr of follow-up. Conclusions and clinical implications: MUSIC practices initiate AS for >50% of patients with 13% incidence of delayed intervention and <1% incidence of metastasis within 3 yr, indicating that AS is a safe and durable option for many patients with cT1RMs. Further investigations into imaging protocols and longer-term outcomes of AS are warranted. Patient summary: In Michigan, most patients diagnosed with localized renal masses of <4 cm and some with tumors up to 7 cm in size elect active surveillance (AS), with a 13% cumulative incidence of undergoing intervention within 3 yr of detection. At 3 yr after initiating AS, the cohort had 90% overall survival and >99% cancer-specific survival, indicating that AS is a safe and durable strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.